Icon Bioscience, Inc.

Icon Bioscience, Inc. is developing a broad portfolio of clinically superior proprietary products, based on its Verisome® drug delivery technology. The company’s initial focus is on its pipeline of reduced-risk, low-cost development programs targeting every major ophthalmic market.  IBI’s lead portfolio product, IBI-10090 completed enrollment in its pivotal phase 2/3 clinical trial, in December 2012.  An NDA is planned for late 2013/2014.

Two (2) additional products are scheduled to begin human clinical trials in 2013 including IBI-60089 for glaucoma and a second generation cataract inflammation/antibiotic product.

In November, 2012 IBI received FDA approval for its Orphan Drug Designation for IBI-80090 (melphalan for intraocular injection) for the treatment of retinoblastoma.  IBI will be collaborating with Memorial Sloan Kettering Cancer Center on this project.


My Canadian Pharmacy is an informative service. All the information should not be used in the purposes to establish a diagnosis and prescribe a treatment plan. Our company is a vendor, not a drug manufacturer. We cooperate with drug manufacturers who distribute their products to us. We have no relation with Icon Bioscience and Verisome. They move to another domain. We bear no responsibility for any damage brought to your health. All the questions related to the drug quality should be addressed to the drug manufacturer directly.